GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biomarin Pharmaceutical Inc (FRA:BM8) » Definitions » Total Inventories

Biomarin Pharmaceutical (FRA:BM8) Total Inventories : €1,177 Mil (As of Dec. 2024)


View and export this data going back to 1999. Start your Free Trial

What is Biomarin Pharmaceutical Total Inventories?

Biomarin Pharmaceutical's total inventories for the quarter that ended in Dec. 2024 was €1,177 Mil. Biomarin Pharmaceutical's average total inventories from the quarter that ended in Sep. 2024 to the quarter that ended in Dec. 2024 was €1,120 Mil.

In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. Biomarin Pharmaceutical's Net-Net Working Capital per share for the quarter that ended in Dec. 2024 was €4.60.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. Biomarin Pharmaceutical's Days Inventory for the three months ended in Dec. 2024 was 785.99.

Inventory Turnover measures how fast the company turns over its inventory within a year. Biomarin Pharmaceutical's Inventory Turnover for the quarter that ended in Dec. 2024 was 0.12.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Biomarin Pharmaceutical's Inventory-to-Revenue for the quarter that ended in Dec. 2024 was 1.57.


Biomarin Pharmaceutical Total Inventories Historical Data

The historical data trend for Biomarin Pharmaceutical's Total Inventories can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biomarin Pharmaceutical Total Inventories Chart

Biomarin Pharmaceutical Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Total Inventories
Get a 7-Day Free Trial Premium Member Only Premium Member Only 574.21 687.35 844.01 1,015.29 1,177.18

Biomarin Pharmaceutical Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Total Inventories Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,015.29 1,046.94 1,099.58 1,062.58 1,177.18

Biomarin Pharmaceutical Total Inventories Calculation

Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.


Biomarin Pharmaceutical  (FRA:BM8) Total Inventories Explanation

Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.

1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.

Biomarin Pharmaceutical's Net-Net Working Capital Per Share for the quarter that ended in Dec. 2024 is

Net-Net Working Capital Per Share (Q: Dec. 2024 )
=(Cash And Cash Equivalents+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(1086.509+0.75 * 630.811+0.5 * 1177.184-1271.057
-0-0)/190.761
=4.60

2. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Biomarin Pharmaceutical's Days Inventory for the three months ended in Dec. 2024 is calculated as:

Days Inventory=Average Total Inventories (Q: Dec. 2024 )/Cost of Goods Sold (Q: Dec. 2024 )*Days in Period
=1119.884/130.013*365 / 4
=785.99

3. Inventory Turnover measures how fast the company turns over its inventory within a year.

Biomarin Pharmaceutical's Inventory Turnover for the quarter that ended in Dec. 2024 is calculated as

Inventory Turnover=Cost of Goods Sold (Q: Dec. 2024 ) / Average Total Inventories (Q: Dec. 2024 )
=130.013 / 1119.884
=0.12

4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Biomarin Pharmaceutical's Inventory to Revenue for the quarter that ended in Dec. 2024 is calculated as

Inventory-to-Revenue=Average Total Inventories (Q: Dec. 2024 ) / Revenue (Q: Dec. 2024 )
=1119.884 / 713.684
=1.57

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.

When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.

Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.


Biomarin Pharmaceutical Total Inventories Related Terms

Thank you for viewing the detailed overview of Biomarin Pharmaceutical's Total Inventories provided by GuruFocus.com. Please click on the following links to see related term pages.


Biomarin Pharmaceutical Business Description

Address
770 Lindaro Street, San Rafael, CA, USA, 94901
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments aimed at addressing complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria (PKU), hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development.

Biomarin Pharmaceutical Headlines

No Headlines